NASDAQ: $ELDN Advancements in Transplantation Science Eledon Pharmaceuticals recently announced promising results from its Phase 2 BESTOW trial, a study evaluating the efficacy and safety of their lead candidate, tegoprubart. This trial focused on patients undergoing kidney transplantation, aiming to address the critical need for more effective immunosuppressive therapies. Understanding the BESTOW Trial Results The…